Difference between revisions of "Team:Stockholm/Attributions"

Line 70: Line 70:
 
<ul>
 
<ul>
 
<div class="row superad-row">
 
<div class="row superad-row">
<div class="col-md-4 col-sm-4 col-xs-4 vesicle"><a href="http://www.healthcap.eu/"><img src="https://static.igem.org/mediawiki/2015/3/3f/Roger_Draheim.png" class="superad"></a></div>
+
<div class="col-md-4 col-sm-4 col-xs-4 vesicle"><a href="http://www.port.ac.uk/school-of-pharmacy-and-biomedical-sciences/staff/roger-draheim-.html"><img src="https://static.igem.org/mediawiki/2015/7/78/Roger_Draheim.jpeg" class="superad"></a></div>
 
<div class="col-md-1 col-sm-1 col-xs-1"></div>
 
<div class="col-md-1 col-sm-1 col-xs-1"></div>
<div class="col-md-7 col-sm-7 col-xs-7"><li><p><b>Roger Draheim</b>, <i>University of Portsmouth</i>, is our primary advisor. He has been formerly working at the Stockholm University and is an expert in the field of Osmoregulation via EnvZ-OmpR pathways. He has been independently conducting similar experiments as we have and we could thus compare our data to his results. Among these experiments, you can find the prediction of EnvZ (extracellular domain) and the characterization of the EnvZ gene in his expression vector from which we derived our EnvZ biobrick (BBa_1766008). In both given examples, we got to similar results and can therefore give a confident conclusion to these results presented. He has provided us with the MDG147 and EPB30 strains which have a genetically integrated YFP/CFP reporter system depending on the phosphorylation status of OmpR. We would like to thank Roger for his advice, feedback and constructive suggestions throughout the entire project.</p></li></div>
+
<div class="col-md-7 col-sm-7 col-xs-7"><li><a href="http://www.port.ac.uk/school-of-pharmacy-and-biomedical-sciences/staff/roger-draheim-.html"><p><b>Roger Draheim</b>, <i>University of Portsmouth</i>, is our primary advisor<a/>. He has been formerly working at the Stockholm University and is an expert in the field of Osmoregulation via EnvZ-OmpR pathways. He has been independently conducting similar experiments as we have and we could thus compare our data to his results. Among these experiments, you can find the prediction of EnvZ (extracellular domain) and the characterization of the EnvZ gene in his expression vector from which we derived our EnvZ biobrick (BBa_1766008). In both given examples, we got to similar results and can therefore give a confident conclusion to these results presented. He has provided us with the MDG147 and EPB30 strains which have a genetically integrated YFP/CFP reporter system depending on the phosphorylation status of OmpR. We would like to thank Roger for his advice, feedback and constructive suggestions throughout the entire project.</p></li></div>
 
</div>
 
</div>
  

Revision as of 13:43, 17 September 2015

Attributions and thanks

All experiments conducted in this project has been designed, executed and analysed by members of the iGEM Group Stockholm. We, as iGEM Team Stockholm, are confidently standing behind the presented data. We have put a special effort not to modify the actual picture that we got by conducting our experiments in any way.

Our project has been developed independently from other projects. We are not really building up on a single project. We discovered that the iGEM Team from Dundee 2013 has been working with a chimeric version of the EnvZ as well. Therefore, we have analysed their project and adjusted our experiments accordingly. After request, we were also very happy to receive the EnvZ deficient E.Coli strain BW25113 from Dundee, in person of Frank Sargent and Chris Earl.

We have been also inspired by the work that has been already conducted with the OmpR signaling cascade. Notably, the former iGEM Teams from Technion Israel.

Supervisors

  • Johan Rockberg, KTH Royal Institute of Technology. He heads a research group at the department of Proteomics and nanotechnology at the KTH School of Biotechnology. His projects are centered on the studying and engineer- ing of binding surfaces of proteins for therapy and development of cell factories for sustainable production of pharmaceuticals in mammalian and microbial hosts.

  • Ute Römling, Karolinska Institutet. She is Professor of Medical Microbial Physiology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. The major research topic of her group is regulation of microbial biofilm formation by cyclic di-GMP second messenger signaling and other factors. In addition, interactions of biofilm forming cells with the host organism and persistence mechanisms are investigated.

  • Håkan Jönsson, KTH Royal Institute of Technology. He is an Assistant Professor at KTH Biotechnology heading the Biomicrofluidics research group at Science for Life Laboratory in Solna. His research centers on microfluidic high throughput single cell analysis and screening in biomedical and biosustainability settings.

  • Teresa Frisan, Karolinska Institutet. She leads a group at the Department of Cell and Molecular Biology at Karolinska Institutet which does research on the carcinogenic properties of chronic infection with CDT-producing bacteria.

At this point, we would like to thank our supervisors who have been accompanying us throughout the entire project. They provided us with invaluable feedback at the weekly meetings, gave us new ideas and promoted our research. We are glad for their engagement for this student-driven research project and that they have been helping us not only scientifically but also administratively to get insurance and a laboratory facility in which we could perform our research in.

Advisor